ProMIS Neurosciences, Inc. (PMN) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 4.13
30Y Low4.1·High4.1
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 3.54
30Y Low1.5·High84.8
ROE
↓
-521.6%
↓+21% vs avg
5yr avg: -660.3%
30Y Low-315%·High27%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PMN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ProMIS Neurosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $68M | $12.0B | $25M | $14M | $33M | $38M | $23M | $34M | $48M | $35M | $17M |
| Enterprise Value | $61M | $12.0B | $12M | $2M | $25M | $22M | $22M | $32M | $45M | $33M | $16M |
| P/E Ratio → | -0.46 | — | 8.62 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 4691.62 | 14599.36 | 28097.68 | 137074.21 | 4445.57 | 8486.31 |
| P/B Ratio | — | — | 1.52 | 3.77 | — | 5.34 | — | 84.83 | 41.37 | 22.81 | 244.69 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PMN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 2665.98 | 13941.87 | 26715.23 | 130227.07 | 4230.83 | 8191.02 |
| EV / EBITDA | — | — | 4.13 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 4.13 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PMN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -521.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | -71796.9% | -203296.1% | -393853.2% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | -101363.6% | -361814.2% | -1009282.5% | -2140431.6% | -60766.7% | -127799.6% |
| Net Profit Margin | — | — | — | — | — | -118662.2% | -361814.2% | -615329.4% | -2140431.6% | -60838.5% | -128390.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -521.6% | -521.6% | 27.5% | -1815.5% | -677.4% | -314.5% | — | -951.7% | -555.1% | -597.4% | -768.0% |
| ROA | -282.8% | -282.8% | 17.1% | -152.3% | -113.5% | -81.1% | -327.4% | -293.5% | -290.6% | -305.1% | -242.7% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -519.5% | -519.5% | -160.5% | -761.7% | -212.9% | -81.5% | — | -1561.0% | -555.1% | -596.7% | -764.4% |
PMN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.69 | — | — | — | — | 1.74 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.81 | -3.36 | — | -2.30 | — | -4.17 | -2.07 | -1.10 | -8.51 |
| Net Debt / EBITDA | — | — | -4.65 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | 37.20 | -88.57 | -63.04 | -22.52 | — | — | — | -846.52 | -161.04 |
Net cash position: cash ($6M) exceeds total debt ($0)
PMN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.88x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.46x to 0.88x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.88 | 0.88 | 8.52 | 1.46 | 1.08 | 19.07 | 0.52 | 1.21 | 1.61 | 3.31 | 1.00 |
| Quick Ratio | 0.88 | 0.88 | 8.52 | 1.46 | 1.08 | 19.07 | 0.52 | 1.21 | 1.63 | 3.36 | 1.04 |
| Cash Ratio | 0.59 | 0.59 | 6.01 | 1.35 | 0.92 | 18.28 | 0.46 | 1.02 | 1.34 | 2.72 | 0.84 |
| Asset Turnover | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 1216.41 | 100.59 | 1262.24 |
PMN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ProMIS Neurosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 11.6% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1.8B | $1M | $491708 | $300104 | $231425 | $190400 | $173197 | $159463 | $137185 | $113264 |
Peer Comparison
Compare PMN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PMNYou | $68M | -0.5 | — | — | — | — | -521.6% | — | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARVN | $489M | -5.9 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 BIIB | $30B | 22.7 | 11.9 | 14.4 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 LLY | $1.1T | 49.4 | 35.4 | 119.3 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ESPR | $655M | -28.6 | 17.1 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 IONS | $12B | -30.8 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ALNY | $38B | 121.4 | 67.0 | 81.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
What if you invested $1,000 in PMN 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PMN be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PMN Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPMN vs PRTA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Prothena Corporation plc.
Compare NowPMN — Frequently Asked Questions
Quick answers to the most common questions about buying PMN stock.
What is ProMIS Neurosciences, Inc.'s P/E ratio?
ProMIS Neurosciences, Inc.'s current P/E ratio is -0.5x. The historical average is 8.6x.
What is ProMIS Neurosciences, Inc.'s ROE?
ProMIS Neurosciences, Inc.'s return on equity (ROE) is -521.6%. The historical average is -95.0%.
Is PMN stock overvalued?
Based on historical data, ProMIS Neurosciences, Inc. is trading at a P/E of -0.5x. Compare with industry peers and growth rates for a complete picture.